Buflomedil

Summary

Buflomedil (CHEMBL188921) is an approved small molecule (ATC C04AX20); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C04AX20
• Indications: 1 condition
• Chemistry: 307.4 Da · C17H25NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL188921
Name	Buflomedil
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2467
ATC	C04AX20
Molecular formula	C17H25NO4
Molecular weight	307.4
InChIKey	OWYLAEYXIQKAOL-UHFFFAOYSA-N

SMILES: COC1=CC(=C(C(=C1)OC)C(=O)CCCN2CCCC2)OC

IUPAC name: 4-pyrrolidin-1-yl-1-(2,4,6-trimethoxyphenyl)butan-1-one

Also known as: Buflomedil, SID11112743, SID26757801, SID174006865, BUFLOMEDIL, BUFLOMEDIL HYDROCHLORIDE, buflomedil

Parent form; salt/anhydrous children: CHEMBL1715107

Patent coverage: 696 distinct patent families (2,488 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,487 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Prelamin-A/C, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, 5-hydroxytryptamine receptor 1A, Kappa-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Histamine H3 receptor, Sigma non-opioid intracellular receptor 1, Cytochrome P450 2D6, C-8 sterol isomerase ERG2, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase.

Bioactivity

ChEMBL activities: 11 potent at pChembl ≥ 5 of 14 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
EBP	7.22	Ki	60	nM	CHEMBL_ACT_1484098
LMNA	6.5	Potency	316.2	nM	CHEMBL_ACT_3638027
SIGMAR1	6.04	Ki	912.2	nM	CHEMBL_ACT_7621326
SIGMAR1	5.89	Ki	1290	nM	CHEMBL_ACT_1484099
SIGMAR1	5.66	IC50	2170	nM	CHEMBL_ACT_7621325
KCNH2	5.58	AC50	2600	nM	CHEMBL_ACT_25118322
OPRK1	5.37	AC50	4300	nM	CHEMBL_ACT_25129720
ADRA2A	5.21	AC50	6100	nM	CHEMBL_ACT_25220195
P32352	5.15	Ki	7150	nM	CHEMBL_ACT_1484100
CYP2D6	5.1	Potency	7943	nM	CHEMBL_ACT_4986130
CYP2D6	5.1	AC50	7943	nM	CHEMBL_ACT_6019808

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).